|
Vietnam Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Vietnam Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Vietnam.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Vietnamese pharmaceutical and healthcare industry.
Competitive intelligence, Vietnamese pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Vietnamese market.
The Vietnam Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Vietnam Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Vietnamese pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Vietnam to test other views – a key input for successful budgeting and strategic business planning in the Vietnamese pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Vietnamese Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Vietnam.
- Exploit The Latest Competitive Vietnamese Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Vietnam.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Vietnam Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Vietnam Pharmaceutical And Healthcare Industry SWOT |
| Vietnam Political SWOT |
| Vietnam Economic SWOT |
| Vietnam Business Environment SWOT |
Chapter - Vietnam – Business Environment Rankings |
| Table: Asia Pacific Pharmaceutical Business Environment Rankings For Q109 |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Market Summary |
| Regulatory Regime |
| Pharmaceutical Advertising |
| Intellectual Property Environment |
| IP Shortcomings |
| Counterfeit Drugs |
| Other Regulatory Issues |
| Pricing And Reimbursement Regime |
Chapter - Industry Trends And Developments |
| Epidemiology |
| Healthcare Financing |
| Healthcare Insurance |
| Healthcare And Pharmaceutical Reforms |
| Foreign Partnerships |
| Domestic Pharmaceutical Sector |
| Recent Pharmaceutical Industry Developments |
| Foreign Pharmaceutical Sector |
| Traditional Medicines |
| Retail Sector |
| Table: Key Aspects Of Good Pharmacy Practice (GPP) In Developing Countries |
| Research And Development |
| Vaccine Sector |
| Biotechnology Sector |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Vietnam – Pharmaceutical Expenditure, 2003-2013 |
| Key Growth Factors – Industry |
| Key Growth Factors – Industry |
| Table: Vietnam – Health Expenditure, 2003-2013 |
| Key Growth Factors – Macroeconomic |
| Table: Vietnam - Economic Activity |
| Prescription Market Forecast |
| Table: Vietnam – Prescription Market Indicators, 2004-2013 (VNDmn unless otherwise stated) |
| OTC Market Forecast |
| Table: Vietnam – OTC Medicine Expenditure, 2004-2013 (VNDmn unless otherwise stated) |
| Patented Market Forecast |
| Patented Market Forecast |
| Table: Vietnam – Patented Product Expenditure, 2003-2013 |
| Generic Market Forecasts |
| Table: Vietnam – Generics Drug Expenditure, 2003-2013 |
| Export/Import Forecasts |
| Table: Vietnam – Pharmaceutical Trade Indicators, 2003-2013 (US$mn) |
| Medical Device Market Forecast |
| Table: Vietnam's Medical Device Market (US$mn unless otherwise stated) |
| Other Healthcare Data Forecasts |
| Table: Vietnam – Other Healthcare Indicators, 2003-2012 |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Profiles |
| Leading Multinational Manufacturers |
| Pfizer |
| Sanofi-Aventis |
| Novartis |
| Merck & Co |
| Indigenous Manufacturer Profiles |
| Vietnam Pharmaceutical Corporation (Vinapharm) |
| Vietnam OPV Pharmaceutical Co |
| Vietnam Pharmaceutical Joint Stock Company (Ampharco) |
| Vidipha Central Pharmaceutical Joint Stock Company |
Chapter - Country Snapshot: Vietnam Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 1999-2004 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Vietnam Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In 2008, Vietnam’s drug market was worth around VND19.8bn (US$1.2bn). By the end of 2013, BMI forecasts that drug expenditure should reach VND35.3bn (US$2bn), representing a compound annual growth rate (CAGR) of 10.9% between 2008 and 2013. In light of the worsening global economic climate, we have revised our 2008 and 2009 drug expenditure growth rates downwards. GDP growth and more moderate inflation will both serve to constrain nominal drug expenditure.
Indeed, a major factor that has caused a downward revision in Vietnam’s drug expenditure forecast this quarter is the risks that the global recession is hitting Asia’s export-focused economies, including Vietnam. With demand for consumer goods declining in key export markets, Vietnam’s economic growth may slow, which is likely to have a knock-on effect on private pharmaceutical consumption.
Vietnam has a relatively strong generics manufacturing industry, which largely caters to the domestic market, since many smaller domestic players do not yet conform to international manufacturing norms. The government has promised to improve pharmaceutical GMP standards, with all domestic manufacturers being expected to comply by 2008. However, the Ministry of Health extended the deadline for domestic producers to obtain GMP certificates to the end of 2010, which will provide some relief to smaller players in particular. Once the domestic industry is GMP compliant, BMI expects the country’s pharmaceutical exports to increase significantly from US$29mn in 2008. Export volumes should receive a further boost from a weakening of the dong. BMI’s Country Risk analysts forecast that the dong will reach VND17,500/US$ in 2013, from VND16,433/US$ in 2008.
Vietnam has a relatively strict pharmaceutical pricing environment and a tender system is run for most public procurement. However, rising import prices have put pressure on domestic companies that have signed fixed supply contracts but rely on imported APIs for manufacturing. According to the Drug Administration of Vietnam (DAV), as many as 25 firms failed to fulfil supply contracts with hospitals, choosing instead to incur penalties amounting to 10-20% of the tender value.
BMI’s updated Business Environment Ratings for Q209 demonstrate that Vietnam is one of least attractive prospects in the Asia region. Of 15 markets surveyed, only Bangladesh is ranked lower. The country’s young population and predominantly rural population serve to limit the potential for drug makers. Having said this, the stable political structure and recent strong economic growth mean that the country is likely to climb the Business Environment league table over the coming years.
|
Vietnam Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan and Thailand |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |